



September 8, 2021

The Honorable Charles Schumer
Majority Leader
U.S. Senate
Washington, DC 20510

The Honorable Nancy Pelosi
Speaker
U.S. House of Representatives
Washington, DC 20515

The Honorable Mitch McConnell
Minority Leader
U.S. Senate
Washington, DC 20510

The Honorable Kevin McCarthy
Minority Leader
U.S. House of Representatives
Washington, DC 20515

Dear Majority Leader Schumer, Speaker Pelosi, Leader McConnell, and Leader McCarthy:

On behalf of home infusion providers, health systems, home health agencies, pharmacists, nurses, patients, and other key stakeholders, we are writing to express our support for bipartisan, bicameral legislation that would ensure Medicare beneficiaries have access to intravenous (IV) medications in the comfort of their own homes.

As the COVID-19 pandemic has brought a spotlight on the value of home-based care and the ability of health care providers to furnish care remotely, the *Preserving Patient Access to Home Infusion Act* ([S. 2652](#); [H.R. 5067](#)) would secure access to home-based IV treatments while also saving taxpayer dollars by shifting care away from more expensive settings. Moreover, independent research demonstrates that up to [95 percent](#) of patients would prefer to receive their infusions at home, and patients who receive their care at home “report significantly better physical and mental well-being and less disruption of family and personal responsibilities.”

The *Preserving Patient Access to Home Infusion Act* provides important clarifications to the *21st Century Cures Act* that will ensure Medicare recognizes the full spectrum of professional services that make home infusion a safe and effective option for patients — including the extensive pharmacist services that minimize the need for face-to-face interactions, which are integral to safe and effective treatment. This will enable the delivery of infused medications in patients’ homes, protect those with underlying health conditions from the risk of disease, provide access in rural and underserved communities, relieve burden on hospitals, and create savings for patients and taxpayers alike.

Commercial payers have long recognized that home infusion is an efficient and cost-effective site of care. As a [report](#) from the Government Accountability Office concluded, “providing infusion therapy at home generally costs less than treatment in other settings... and is largely free from inappropriate utilization and problems in quality of care.” Moreover, the Congressional Budget Office has consistently [concluded](#) that enhanced beneficiary access to home infusion will create savings for the Medicare program, and an independent [analysis](#) from The Moran Company estimates this legislation would create \$93 million in budgetary savings over 10 years.

If you have questions or seek any additional information, please contact Connie Sullivan, President and CEO of the National Home Infusion Association (NHIA) at Connie.Sullivan@NHIA.org. We appreciate your attention to this issue and thank you for your diligent stewardship of the Medicare program.

Sincerely,

National Home Infusion Association
Advocate Aurora Health
Alliance for Pharmacy Compounding
American Academy of Home Care Medicine
American Association of Heart Failure Nurses
American Association of Neuromuscular & Electrodiagnostic Medicine
American Society for Parenteral and Enteral Nutrition
American Society of Consultant Pharmacists
CSL Behring
Fairview Pharmacy Services
GBS|CIDP Foundation International
Grifols
Healthcare Nutrition Council
Immune Deficiency Foundation
Infusion Nurses Society
Managed Health Care Associates, Inc.
National Association for Home Care & Hospice
National Community Pharmacists Association
NTM Info and Research Inc.
Patient Services Inc.
Plasma Protein Therapeutics Association
Premier Healthcare Alliance
Senior Care Pharmacy Coalition
US Hereditary Angioedema Association